Novartis, Ranbaxy argue over Diovan patent

Meanwhile, Novartis is suing the Indian generics giant Ranbaxy Laboratories over a copycat version of Diovan. Novartis says the blood pressure med--its top seller--is protected by a patent that doesn't expire until 2012. Ranbaxy, however, claims that the patent is invalid.

The generics firm had applied for FDA approval for its version of Diovan, originally stating that it would wait for the patent to expire to sell the drug. But Ranbaxy amended its application in late June to say that it intends to market its version of Diovan. 

- see the complaint

Related Articles:
Indian court spurns Novartis on patent challenge. Report
Novartis patent challenge spurs protests in India. Report
Standards on biotech patents get tougher. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.